TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07815678: First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671

Sponsor: Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 164 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$6,180,180

Rescue Site Savings

+$4,091,900

Unlock Full NCT07815678 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07815678 Rescue Dossier →